AGIOS PHARMACEUTICALS, INC. Costs and Expenses
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Costs and Expenses of $155.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2026-06-30 was $155.30M, a 11.32% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2026-03-31 was $130.77M, a 13.36% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2025-12-31 was $141.54M, a 4.26% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2025-09-30 was $129.75M, a 16.08% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. costs and expenses for fiscal 2025 was $526.16M, a 13.83% increase from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. costs and expenses for fiscal 2024 was $462.24M, a 10.50% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. costs and expenses for fiscal 2023 was $418.31M, a 3.73% increase from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. costs and expenses for fiscal 2022 was $403.29M, a 6.57% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $155.30M 10-Q · filed 2026-07-30 | $286.07M 10-Q · filed 2026-07-30 | $427.61M derived: sum of 3 quarters · filed 2026-07-30 | $557.36M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $130.77M 10-Q · filed 2026-04-29 | $272.32M derived: sum of 2 quarters · filed 2026-04-29 | $402.06M derived: sum of 3 quarters · filed 2026-04-29 | $541.58M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $141.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $271.29M derived: sum of 2 quarters · filed 2026-02-12 | $410.81M derived: sum of 3 quarters · filed 2026-07-30 | $526.16M 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | $129.75M 10-Q · filed 2025-10-30 | $269.26M derived: sum of 2 quarters · filed 2026-07-30 | $384.62M 10-Q · filed 2025-10-30 | $520.38M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $139.51M 10-Q · filed 2026-07-30 | $254.87M 10-Q · filed 2026-07-30 | $390.63M derived: sum of 3 quarters · filed 2026-07-30 | $502.41M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $115.36M 10-Q · filed 2026-04-29 | $251.12M derived: sum of 2 quarters · filed 2026-04-29 | $362.90M derived: sum of 3 quarters · filed 2026-04-29 | $477.33M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $135.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $247.54M derived: sum of 2 quarters · filed 2026-02-12 | $361.97M derived: sum of 3 quarters · filed 2026-02-12 | $462.24M 10-K · filed 2026-02-12 | ||||
| 2024-09-30 | $111.78M 10-Q · filed 2025-10-30 | $226.21M derived: sum of 2 quarters · filed 2025-10-30 | $326.47M 10-Q · filed 2025-10-30 | $439.85M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-06-30 | $114.43M 10-Q · filed 2025-07-31 | $214.69M 10-Q · filed 2025-07-31 | $328.07M derived: sum of 3 quarters · filed 2026-02-12 | $436.37M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-03-31 | $100.26M 10-Q · filed 2025-05-01 | $213.64M derived: sum of 2 quarters · filed 2026-02-12 | $321.94M derived: sum of 3 quarters · filed 2026-02-12 | $422.35M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2023-12-31 | $113.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $221.68M derived: sum of 2 quarters · filed 2026-02-12 | $322.09M derived: sum of 3 quarters · filed 2026-02-12 | $418.31M 10-K · filed 2026-02-12 | ||||
| 2023-09-30 | $108.30M 10-Q · filed 2024-10-31 | $208.71M derived: sum of 2 quarters · filed 2024-10-31 | $304.93M 10-Q · filed 2024-10-31 | $408.41M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $100.41M 10-Q · filed 2024-08-01 | $196.63M 10-Q · filed 2024-08-01 | $300.12M derived: sum of 3 quarters · filed 2025-02-13 | $394.72M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $96.22M 10-Q · filed 2024-05-02 | $199.70M derived: sum of 2 quarters · filed 2025-02-13 | $294.31M derived: sum of 3 quarters · filed 2025-02-13 | $397.53M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $103.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $198.09M derived: sum of 2 quarters · filed 2025-02-13 | $301.31M derived: sum of 3 quarters · filed 2025-02-13 | $403.29M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $94.61M 10-Q · filed 2023-11-02 | $197.83M derived: sum of 2 quarters · filed 2023-11-02 | $299.81M 10-Q · filed 2023-11-02 | $404.63M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $103.22M 10-Q · filed 2023-08-03 | $205.20M 10-Q · filed 2023-08-03 | $310.03M derived: sum of 3 quarters · filed 2024-02-15 | $401.18M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $101.98M 10-Q · filed 2023-05-04 | $206.80M derived: sum of 2 quarters · filed 2024-02-15 | $297.96M derived: sum of 3 quarters · filed 2024-02-15 | $389.18M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $104.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $195.98M derived: sum of 2 quarters · filed 2024-02-15 | $287.20M derived: sum of 3 quarters · filed 2024-02-15 | $378.42M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $91.15M 10-Q · filed 2022-11-03 | $182.37M derived: sum of 2 quarters · filed 2022-11-03 | $273.59M 10-Q · filed 2022-11-03 | $358.92M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $91.22M 10-Q · filed 2022-08-04 | $182.44M 10-Q · filed 2022-08-04 | $267.77M derived: sum of 3 quarters · filed 2023-02-23 | $348.06M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $91.22M 10-Q · filed 2022-05-05 | $176.55M derived: sum of 2 quarters · filed 2023-02-23 | $256.84M derived: sum of 3 quarters · filed 2023-02-23 | $340.10M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $85.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $165.62M derived: sum of 2 quarters · filed 2023-02-23 | $248.89M derived: sum of 3 quarters · filed 2023-02-23 | $335.92M 10-K · filed 2023-02-23 | $519.35M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $80.29M 10-Q · filed 2021-11-03 | $125.03M 10-Q · filed 2020-11-05 | $163.55M derived: sum of 2 quarters · filed 2021-11-03 | $250.58M 10-Q · filed 2021-11-03 | $382.87M 10-Q · filed 2020-11-05 | $163.98M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | $83.26M 10-Q · filed 2021-07-29 | $127.54M 10-Q · filed 2020-07-30 | $170.29M 10-Q · filed 2021-07-29 | $257.83M 10-Q · filed 2020-07-30 | $83.69M derived: sum of 3 quarters · filed 2022-02-24 | $218.77M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | $87.03M 10-Q · filed 2021-04-29 | $130.29M 10-Q · filed 2020-04-30 | $423.00K derived: sum of 2 quarters · filed 2022-02-24 | $135.51M derived: sum of 3 quarters · filed 2022-02-24 | $275.59M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | -$86.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $48.48M derived: sum of 2 quarters · filed 2022-02-24 | $188.56M derived: sum of 3 quarters · filed 2022-02-24 | $316.27M 10-K · filed 2022-02-24 | $544.25M 10-K · filed 2020-02-19 | |||
| 2019-09-30 | $135.08M 10-Q · filed 2020-11-05 | $275.17M derived: sum of 2 quarters · filed 2020-11-05 | $402.88M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $140.08M 10-Q · filed 2020-07-30 | $267.79M 10-Q · filed 2020-07-30 | ||||||
| 2019-03-31 | $127.71M 10-Q · filed 2020-04-30 | |||||||
| 2018-12-31 | $456.87M 10-K · filed 2021-02-25 | |||||||
| 2017-12-31 | $363.81M 10-K · filed 2020-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |